Image source: Getty Images.
After U.S. patent regulators invalidated the third of five patents protecting Copaxone sales, shares in Teva Pharmaceutical (NYSE: TEVA) fell steadily throughout October to finish down 7.1% on the month, according to S&P Global Market Intelligence.